Logo

Stratagene to Seek Licensing Revenues Following PCR Settlement

May 16, 2006

NEW YORK, May 16 (GenomeWeb News) - Stratagene said today that its recent settlement of a patent dispute with Takara Bio related to PCR enzyme blends has "significantly strengthened its patent portfolio" in this area.

 

As such, Stratagene said, it now owns a broad USpatent portfolio covering its enzyme blends, and will seek to establish a licensing program for competitors' products covered by the portfolio.

 

"We believe that there are a number of competitors selling products that are covered under our patent portfolio," Joseph Sorge, president and CEO of Stratagene, said in a statement. "It is our intention to make limited licenses available and recognize resulting licensing revenue."

 

As GenomeWeb News reported last week, Stratagene and Takara Bio have reached a settlement under which the firms have agreed to pay "reasonable" royalties to each other under certain licensed patents, and each company will be free to independently license its patents to third parties.

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.